Steven Suh, MD
Ophthalmology · Westerville, OHNPI 1023011475
Payments from drug & device makers
Across 144 payments — averaging $37.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Microsurgical Technology, Inc.$3K
- Tarsus Pharmaceuticals, Inc.$444
- Alcon$329
- AbbVie$300
- Sun Pharmaceutical Industries Inc.$282
- Oyster Point Pharma, Inc.$251
- plus $1K from 17 others
What the payments were for
- Food & beverage$2,76452%
- Gifts$190%
- Charitable contribution$2,55048%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Microsurgical Technology, Inc. | 1 | $2,550 |
| Tarsus Pharmaceuticals, Inc. | 18 | $444 |
| Alcon | 13 | $329 |
| AbbVie | 20 | $300 |
| Sun Pharmaceutical Industries Inc. | 14 | $282 |
| Oyster Point Pharma, Inc. | 15 | $251 |
| Bausch & Lomb Americas Inc. | 12 | $237 |
| Novartis | 11 | $219 |
| Amgen(2 entities) | 7 | $139 |
| Eyevance Pharmaceuticals LLC | 8 | $123 |
| Glaukos Corporation | 4 | $90 |
| Biotissue Holdings Inc. | 3 | $63 |
| Dompe US, Inc. | 3 | $61 |
| Rxsight Inc | 3 | $49 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $40 |
| Aerie Pharmaceuticals, Inc. | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Harrow Eye, LLC | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
| Kala Pharmaceuticals, Inc. | 1 | $17 |
| NEW World Medical,inc. | 1 | $15 |
| Tearlab Corp | 1 | $15 |
How this compares
$5,334 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 26 | $42,263 |
| VyzultaLatanoprostene Bunod | 24 | $13,980 |
| LumiganBimatoprost | 29 | $11,578 |
| Latanoprost | 1,112 | $10,693 |
| Brimonidine Tartrate | 112 | $9,029 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $7,715 |
| RhopressaNetarsudil Mesylate | 12 | $7,375 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $5,216 |
| Timolol Maleate | 386 | $3,925 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 37 | $3,258 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 185 | $3,183 |
| Prednisolone Acetate | 59 | $2,705 |
| Fluorometholone | 47 | $2,610 |
| Dorzolamide Hcl | 88 | $1,410 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 39 | $288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $300 | $59,05669 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $30 | $15,09026 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $237 | $13,98024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Westerville
- Kenneth BeckmanWesterville$842K
- John PajkaLima$17.7M
- Justis EhlersCleveland$5M
- Lawrence SingermanBeachwood$3.9M
- Sunil SrivastavaCleveland$2.8M
- Daniel MillerCincinnati$2.3M
- Jonathan LassCleveland$1.9M
- William WileyCleveland$1.9M
- Peter KaiserCleveland$1.5M
- David RogersColumbus$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.